TrialTracker_MD said:

Short answer: the data supports it for most people

I respect TrialTracker_MD perspective but I think this oversimplifies things a bit. Re: Comparative pharmacokinetics — the effect size varies considerably by population.

I am not saying TrialTracker_MD wrong entirely — just that the picture is more nuanced than a blanket statement. The SUSTAIN data specifically shows different outcomes in different metabolic phenotypes.

Relevant to Comparative pharmacokinetics — here is my latest bloodwork comparison:

Key improvements: A1C 8.0% → 5.3%, triglycerides 235 → 105 mg/dL, hsCRP 6.0 → 1.1 mg/L. All on tirzepatide for 15 months.

The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.

Thank you Dr.KarenChen! This is incredibly helpful. Bookmarking for later. 🙏

Slightly tangential to Comparative but nancy_portland reminded me — has the insurance landscape changed recently?

I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.

Moderator note: Reminder: nothing posted here constitutes medical advice. Consult your healthcare provider.

Tagging this for the weekly digest. 👍